Dupixent Improves Severe Asthma Symptoms in a Real-World Setting, but Switching May Require Eosinophil Monitoring

May 16, 2022

Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%. There were some reports of adverse events associated with high eosinophil levels in patients who switched to Dupixent after taking a different biologic.

5 Exacerbation-prone Phenotypes Were Discovered Among Asthma and COPD Patients

April 14, 2022

Five phenotype clusters were discovered to be associated with the exacerbation, or worsening, of chronic inflammatory airway diseases of asthma and chronic obstructive pulmonary disease (COPD), according to a recent study published in PLOS ONE.

FDA Updates for Week of March 14, 2022

March 19, 2022

FDA approves first generic of Symbicort for asthma and COPD and first therapy for rare seizure disorder, Rinvoq and Lynparza get nods for new indications, the agency approves a new delivery system for Alzheimer’s therapy, regulators extend review for Opzelura for skin condition and issue CRL for Fasenra for chronic rhinosinusitis.

Many Young Adults with Asthma Aren't Completely Prepped to Transition to Adult Asthma Care

November 23, 2021

Young adults with asthma were recently surveyed on their preparation of the transition to adult asthma care. Half of all those surveyed did not remember being introduced to concepts of transitioning care, including asthma self-management, by their pediatric asthma provider.